Adult Neurogenesis 2018 952x200px

Parkinson's disease treatment: the current and future landscape

​​Professor Roger Barker, Professor of Clinical Neuroscience, University of Cambridge.

Professor Barker explains where we are with research in 2019 and how our understanding of the disease has progressed, before exploring emerging trends and therapies.

Emerging trends discussed include the role of alpha-synuclein, drug repurposing, providing ‘fertilizer’ to dopamine cells such as in GDNF trials, stem cell-derived dopamine replacement, and gene therapy.

15:55 minutes - Professor Roger Barker, Professor of Clinical Neuroscience, University of Cambridge.


Key cell and neuronal markers from Abcam

To help you get ahead in your Parkinson’s research, we’ve compiled the best neuronal markers to use in conjunction with our disease-specific antibodies.


Neural markers

Marker group

Recommended product

Ki67

Proliferating cell marker

ab16667

GFAP

Schwann cell/Radial glia/Astrocyte

ab33922, ab68428

VIM

Radial Glia

ab92547

NeuN

Mature neuron

ab177487

MAP2

Mature neuron

ab183830

TUBB3

Immature neuron

ab78078

MBP

Oligodendrocyte

ab218011

PSD95

Mature neuron

ab18258

NES

Radial Glia

ab105389, ab6142

DCX

Immature neuron

ab18723

SYP

Mature neuron

ab32127

NOTCH1

Astrocyte

ab52627

TH

Serotonergic neuron/Dopaminergic neuron

ab137869

S100B

Astrocyte

ab52642

MAPT

Mature neuron/Axons

ab80579, ab32057, ab109390 (phospho S396)





登録